blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3472162

EP3472162 - HETEROARYL ESTROGEN RECEPTOR MODULATORS AND USES THEREOF [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  23.09.2022
Database last updated on 20.05.2024
FormerThe patent has been granted
Status updated on  18.10.2021
FormerGrant of patent is intended
Status updated on  28.06.2021
FormerExamination is in progress
Status updated on  26.05.2020
FormerRequest for examination was made
Status updated on  22.03.2019
FormerThe international publication has been made
Status updated on  28.12.2017
Formerunknown
Status updated on  07.07.2017
Most recent event   Tooltip27.04.2024Lapse of the patent in a contracting state
New state(s): MK		published on 29.05.2024 [2024/22]
Applicant(s)For all designated states
F. Hoffmann-La Roche AG
Grenzacherstrasse 124
4070 Basel / CH
[2019/17]
Inventor(s)01 / GOODACRE, Simon Charles
c/o Argenta Discovery 2009 Limited
8/9 Spire Green Centre
Flex Meadow
Harlow Essex CM19 5TR / GB
02 / LABADIE, Sharada
c/o Genentech, Inc.
1 DNA Way
South San Francisco, California 94080 / US
03 / LI, Jun
c/o Genentech, Inc.
1 DNA Way
South San Francisco, California 94080 / US
04 / LIANG, Jun
c/o Genentech, Inc.
1 DNA Way
South San Francisco, California 94080 / US
05 / LIAO, Jiangpeng
c/o WuXi AppTec Co., Ltd.
288 Fute Zhong Road
Waigaoqiao Free Trade Zone
Shanghai 200131 / CN
06 / ORTWINE, Daniel Fred
c/o Genentech, Inc.
1 DNA Way
South San Francisco, California 94080 / US
07 / RAY, Nicholas Charles
c/o Argenta Discovery 2009 Limited
8/9 Spire Green Centre
Flex Meadow
Harlow Essex CM19 5TR / GB
08 / WANG, Xiaojing
c/o Genentech, Inc.
1 DNA Way
South San Francisco, California 94080 / US
09 / ZBIEG, Jason
c/o Genentech, Inc.
1 DNA Way
South San Francisco, California 94080 / US
10 / ZHANG, Birong
c/o Genentech, Inc.
1 DNA Way
South San Francisco, California 94080 / US
 [2019/17]
Representative(s)Neuhaus, Christian Michel, et al
F. Hoffmann-La Roche AG
Grenzacherstrasse 124
4070 Basel / CH
[2019/17]
Application number, filing date17733754.015.06.2017
[2019/17]
WO2017EP64650
Priority number, dateUS201662350885P16.06.2016         Original published format: US 201662350885 P
WO2017CN8724106.06.2017         Original published format: PCT/CN2017/087241
[2019/17]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2017216279
Date:21.12.2017
Language:EN
[2017/51]
Type: A1 Application with search report 
No.:EP3472162
Date:24.04.2019
Language:EN
The application published by WIPO in one of the EPO official languages on 21.12.2017 takes the place of the publication of the European patent application.
[2019/17]
Type: B1 Patent specification 
No.:EP3472162
Date:17.11.2021
Language:EN
[2021/46]
Search report(s)International search report - published on:EP21.12.2017
ClassificationIPC:C07D471/04, C07D471/14, C07D471/20, C07D487/04, C07D491/04, C07D495/04, A61K31/7056, A61P35/00
[2019/17]
CPC:
C07D491/04 (EP); A61P13/08 (EP); A61P15/00 (EP);
A61P35/00 (EP); A61P43/00 (EP); C07D471/04 (EP);
C07D471/14 (EP); C07D471/20 (EP); C07D487/04 (EP);
C07D495/04 (EP) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2019/17]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:HETEROARYL-ÖSTROGENREZEPTORMODULATOREN UND VERWENDUNGEN DAVON[2019/17]
English:HETEROARYL ESTROGEN RECEPTOR MODULATORS AND USES THEREOF[2019/17]
French:MODULATEURS DES RÉCEPTEURS DES ESTROGÈNES HÉTÉROARYLES ET LEURS UTILISATIONS[2019/17]
Entry into regional phase16.01.2019National basic fee paid 
16.01.2019Designation fee(s) paid 
16.01.2019Examination fee paid 
Examination procedure16.01.2019Examination requested  [2019/17]
16.01.2019Date on which the examining division has become responsible
08.08.2019Amendment by applicant (claims and/or description)
29.05.2020Despatch of a communication from the examining division (Time limit: M04)
08.09.2020Reply to a communication from the examining division
15.12.2020Despatch of a communication from the examining division (Time limit: M02)
10.02.2021Reply to a communication from the examining division
29.06.2021Communication of intention to grant the patent
07.10.2021Fee for grant paid
07.10.2021Fee for publishing/printing paid
07.10.2021Receipt of the translation of the claim(s)
Opposition(s)18.08.2022No opposition filed within time limit [2022/43]
Fees paidRenewal fee
10.06.2019Renewal fee patent year 03
31.03.2020Renewal fee patent year 04
08.06.2021Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU15.06.2017
AL17.11.2021
AT17.11.2021
CY17.11.2021
CZ17.11.2021
DK17.11.2021
EE17.11.2021
ES17.11.2021
FI17.11.2021
HR17.11.2021
IT17.11.2021
LT17.11.2021
LV17.11.2021
MC17.11.2021
MK17.11.2021
NL17.11.2021
PL17.11.2021
RO17.11.2021
RS17.11.2021
SE17.11.2021
SI17.11.2021
SK17.11.2021
SM17.11.2021
BG17.02.2022
NO17.02.2022
GR18.02.2022
IS17.03.2022
PT17.03.2022
IE15.06.2022
LU15.06.2022
BE30.06.2022
[2024/22]
Former [2024/20]HU15.06.2017
AL17.11.2021
AT17.11.2021
CY17.11.2021
CZ17.11.2021
DK17.11.2021
EE17.11.2021
ES17.11.2021
FI17.11.2021
HR17.11.2021
IT17.11.2021
LT17.11.2021
LV17.11.2021
MC17.11.2021
NL17.11.2021
PL17.11.2021
RO17.11.2021
RS17.11.2021
SE17.11.2021
SI17.11.2021
SK17.11.2021
SM17.11.2021
BG17.02.2022
NO17.02.2022
GR18.02.2022
IS17.03.2022
PT17.03.2022
IE15.06.2022
LU15.06.2022
BE30.06.2022
Former [2024/18]HU15.06.2017
AL17.11.2021
AT17.11.2021
CZ17.11.2021
DK17.11.2021
EE17.11.2021
ES17.11.2021
FI17.11.2021
HR17.11.2021
IT17.11.2021
LT17.11.2021
LV17.11.2021
MC17.11.2021
NL17.11.2021
PL17.11.2021
RO17.11.2021
RS17.11.2021
SE17.11.2021
SI17.11.2021
SK17.11.2021
SM17.11.2021
BG17.02.2022
NO17.02.2022
GR18.02.2022
IS17.03.2022
PT17.03.2022
IE15.06.2022
LU15.06.2022
BE30.06.2022
Former [2023/25]AL17.11.2021
AT17.11.2021
CZ17.11.2021
DK17.11.2021
EE17.11.2021
ES17.11.2021
FI17.11.2021
HR17.11.2021
IT17.11.2021
LT17.11.2021
LV17.11.2021
MC17.11.2021
NL17.11.2021
PL17.11.2021
RO17.11.2021
RS17.11.2021
SE17.11.2021
SI17.11.2021
SK17.11.2021
SM17.11.2021
BG17.02.2022
NO17.02.2022
GR18.02.2022
IS17.03.2022
PT17.03.2022
IE15.06.2022
LU15.06.2022
BE30.06.2022
Former [2023/21]AL17.11.2021
AT17.11.2021
CZ17.11.2021
DK17.11.2021
EE17.11.2021
ES17.11.2021
FI17.11.2021
HR17.11.2021
LT17.11.2021
LV17.11.2021
MC17.11.2021
NL17.11.2021
PL17.11.2021
RO17.11.2021
RS17.11.2021
SE17.11.2021
SI17.11.2021
SK17.11.2021
SM17.11.2021
BG17.02.2022
NO17.02.2022
GR18.02.2022
IS17.03.2022
PT17.03.2022
IE15.06.2022
LU15.06.2022
Former [2023/20]AL17.11.2021
AT17.11.2021
CZ17.11.2021
DK17.11.2021
EE17.11.2021
ES17.11.2021
FI17.11.2021
HR17.11.2021
LT17.11.2021
LV17.11.2021
MC17.11.2021
NL17.11.2021
PL17.11.2021
RO17.11.2021
RS17.11.2021
SE17.11.2021
SI17.11.2021
SK17.11.2021
SM17.11.2021
BG17.02.2022
NO17.02.2022
GR18.02.2022
IS17.03.2022
PT17.03.2022
IE15.06.2022
Former [2023/08]AL17.11.2021
AT17.11.2021
CZ17.11.2021
DK17.11.2021
EE17.11.2021
ES17.11.2021
FI17.11.2021
HR17.11.2021
LT17.11.2021
LV17.11.2021
MC17.11.2021
NL17.11.2021
PL17.11.2021
RO17.11.2021
RS17.11.2021
SE17.11.2021
SI17.11.2021
SK17.11.2021
SM17.11.2021
BG17.02.2022
NO17.02.2022
GR18.02.2022
IS17.03.2022
PT17.03.2022
Former [2023/01]AL17.11.2021
AT17.11.2021
CZ17.11.2021
DK17.11.2021
EE17.11.2021
ES17.11.2021
FI17.11.2021
HR17.11.2021
LT17.11.2021
LV17.11.2021
NL17.11.2021
PL17.11.2021
RO17.11.2021
RS17.11.2021
SE17.11.2021
SI17.11.2021
SK17.11.2021
SM17.11.2021
BG17.02.2022
NO17.02.2022
GR18.02.2022
IS17.03.2022
PT17.03.2022
Former [2022/49]AL17.11.2021
AT17.11.2021
CZ17.11.2021
DK17.11.2021
EE17.11.2021
ES17.11.2021
FI17.11.2021
HR17.11.2021
LT17.11.2021
LV17.11.2021
NL17.11.2021
PL17.11.2021
RO17.11.2021
RS17.11.2021
SE17.11.2021
SK17.11.2021
SM17.11.2021
BG17.02.2022
NO17.02.2022
GR18.02.2022
IS17.03.2022
PT17.03.2022
Former [2022/35]AT17.11.2021
CZ17.11.2021
DK17.11.2021
EE17.11.2021
ES17.11.2021
FI17.11.2021
HR17.11.2021
LT17.11.2021
LV17.11.2021
NL17.11.2021
PL17.11.2021
RO17.11.2021
RS17.11.2021
SE17.11.2021
SK17.11.2021
SM17.11.2021
BG17.02.2022
NO17.02.2022
GR18.02.2022
IS17.03.2022
PT17.03.2022
Former [2022/34]AT17.11.2021
EE17.11.2021
ES17.11.2021
FI17.11.2021
HR17.11.2021
LT17.11.2021
LV17.11.2021
NL17.11.2021
PL17.11.2021
RO17.11.2021
RS17.11.2021
SE17.11.2021
SM17.11.2021
BG17.02.2022
NO17.02.2022
GR18.02.2022
IS17.03.2022
PT17.03.2022
Former [2022/33]AT17.11.2021
ES17.11.2021
FI17.11.2021
HR17.11.2021
LT17.11.2021
LV17.11.2021
NL17.11.2021
PL17.11.2021
RS17.11.2021
SE17.11.2021
SM17.11.2021
BG17.02.2022
NO17.02.2022
GR18.02.2022
IS17.03.2022
PT17.03.2022
Former [2022/25]AT17.11.2021
ES17.11.2021
FI17.11.2021
HR17.11.2021
LT17.11.2021
LV17.11.2021
NL17.11.2021
PL17.11.2021
RS17.11.2021
SE17.11.2021
BG17.02.2022
NO17.02.2022
GR18.02.2022
IS17.03.2022
PT17.03.2022
Former [2022/24]AT17.11.2021
ES17.11.2021
FI17.11.2021
HR17.11.2021
LT17.11.2021
LV17.11.2021
NL17.11.2021
PL17.11.2021
RS17.11.2021
SE17.11.2021
BG17.02.2022
GR18.02.2022
IS17.03.2022
PT17.03.2022
Former [2022/23]AT17.11.2021
ES17.11.2021
FI17.11.2021
HR17.11.2021
LT17.11.2021
LV17.11.2021
PL17.11.2021
RS17.11.2021
BG17.02.2022
PT17.03.2022
Former [2022/22]AT17.11.2021
FI17.11.2021
LT17.11.2021
RS17.11.2021
BG17.02.2022
Former [2022/21]AT17.11.2021
RS17.11.2021
BG17.02.2022
Former [2022/19]BG17.02.2022
Cited inInternational search[AD]WO0151056  (ASTRAZENECA AB [SE], et al) [AD] 1-35;
 [A]WO2010138706  (PTC THERAPEUTICS INC [US], et al) [A] 1-35* page 1, paragraph 1; example -; claim - *;
 [AD]WO2013090829  (ARAGON PHARMACEUTICALS INC [US]) [AD] 1-35 * page 1, paragraph 2; example -; claim - *;
 [A]WO2015161373  (UNIVERSITÉ DE MONTRÉAL [CA]) [A] 1-35 * page 1, paragraph 1; example 11 *;
 [A]  - MARK J. THOMPSON ET AL, "Synthesis and Evaluation of 1-Amino-6-halo-[beta]-carbolines as Antimalarial and Antiprion Agents", CHEMMEDCHEM, (20120124), vol. 7, no. 4, doi:10.1002/cmdc.201200002, ISSN 1860-7179, pages 578 - 586, XP055242215 [A] 1-35 * table 1, compounds e, f, g *

DOI:   http://dx.doi.org/10.1002/cmdc.201200002
by applicantUS3773919
 WO9615111
 US6774122
 WO2007044515
 US7456160
 US7514444
 US8329680
 US8466139
 WO2013090836
 WO2014045156
    - The Chemistry of Heterocyclic Compounds, A series of Monographs, John Wiley & Sons, (19500000), vol. 13 , 14,
    - J. AM. CHEM. SOC., Heterocyclyl, (19600000), vol. 82, page 5566
    - CHEMICAL ABSTRACTS, Database accession no. 936563-96-1
    - CHEMICAL ABSTRACTS, Database accession no. 1146702-54-6
    - CHEMICAL ABSTRACTS, Database accession no. 51-21-8
    - CHEMICAL ABSTRACTS, Database accession no. 391210-10-9
    - CHEMICAL ABSTRACTS, Database accession no. 15663-27-1
    - CHEMICAL ABSTRACTS, Database accession no. 41575-94-4
    - CHEMICAL ABSTRACTS, Database accession no. 85622-93-1
    - CHEMICAL ABSTRACTS, Database accession no. 23214-92-8
    - ANGEW CHEM., Intl. Ed. Engl., (19940000), vol. 33, pages 183 - 186
    - Biochem. Pharmacol., (19730000), vol. 22, page 3099
    - GRONEMEYER; LAUDET, Protein Profile, (19950000), vol. 2, pages 1173 - 1308
    - GREENFIELD et al., Biochemistry, (20010000), vol. 40, pages 6646 - 6652
    - WELBOREN et al., Endocrine-Related Cancer, (20090000), vol. 16, pages 1073 - 1089
    - KLINGE, Steroid, (20000000), vol. 65, pages 227 - 251
    - BRZOZOWSKI et al., Nature, (19970000), vol. 389, pages 753 - 758
    - WARD; WEIGEL, Biofactors, (20090000), vol. 35, pages 528 - 536
    - TAMRAZI et al., Mol. Endocrinol, (20030000), vol. 17, pages 2593 - 2602
    - REID et al., Mol Cell, (20030000), vol. 11, pages 695 - 707
    - HOWELL A, Endocr Relat Cancer, (20060000), vol. 13, pages 689 - 706
    - PUHALLA S et al., Mol Oncol, (20120000), vol. 6, no. 2, pages 222 - 236
    - LI S et al., Cell Rep, (20130000), vol. 4, no. 6, pages 1116 - 1130
    - MERENBAKH-LAMIN K et al., Cancer Res, (20130000), vol. 73, no. 23, pages 6856 - 6864
    - ROBINSON DR et al., Nat Genet, (20130000), vol. 45, no. 12, pages 1446 - 1451
    - TOY W et al., Nat Genet, (20130000), vol. 45, no. 12, pages 1439 - 1445
    - JESELSOHN R et al., Clin Cancer Res, (20140000), vol. 20, pages 1757 - 1767
    - ASHBY, J. et al., Regulatory toxicology and pharmacology : RTP, (19970000), vol. 25, no. 3, pages 226 - 31
    - Remington's Pharmaceutical Sciences, Mack Publishing Co.
    - Comprehensive Heterocyclic Chemistry II, Elsevier, (19970000), vol. 3
    - Liebigs Annalen der Chemie, (19850000), vol. 9, pages 1910 - 16
    - Helvetica Chimica Acta, (19580000), vol. 41, pages 1052 - 60
    - Arzneimittel-Forschung, (19900000), vol. 40, no. 12, pages 1328 - 31
    - LOUIS F. FIESER; MARY FIESER, Reagents for Organic Synthesis,, Wiley, (19670000), vol. 1-23
    - Beilsteins Handbuch der organischen Chemie, Springer-Verlag
    - LOCHMULLER, C. H., J. Chromatogr, (19750000), vol. 113, no. 3, pages 283 - 302
    - E.; WILEN, S., Stereochemistry of Organic Compounds, John Wiley & Sons, Inc., (19940000), page 322
    - JACOB III., J. Org. Chem., (19820000), vol. 47, page 4165
    - OKAMOTO, J. Chromatogr., (19900000), vol. 513, pages 375 - 378
    - J. Med. Chem., (20090000), vol. 52, no. 4, pages 904 - 907
    - CHEMICAL ABSTRACTS, Database accession no. 145349-17-3
    - CHEMICAL ABSTRACTS, Database accession no. 1443984-69-7
    - CHEMICAL ABSTRACTS, Database accession no. 120-72-9
    - CHEMICAL ABSTRACTS, Database accession no. 1192-01-4
    - CHEMICAL ABSTRACTS, Database accession no. 879121-42-3
    - CHEMICAL ABSTRACTS, Database accession no. 25895-60-7
    - CHEMICAL ABSTRACTS, Database accession no. 15467-31-9
    - CHEMICAL ABSTRACTS, Database accession no. 1538772-53-0
    - CHEMICAL ABSTRACTS, Database accession no. 1206630-22-9
    - MENDOZA et al., Cancer Res., (20020000), vol. 62, pages 5485 - 5488
    - TAN N et al., Clin. Cancer Res., (20110000), vol. 17, no. 6, pages 1394 - 1404
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.